Woburn, Mass. – May 13, 2019 − Aphios Corporation today announced that it has been granted Japanese Patent No. 2015-545195 by the Japan Patent Office. The patent, entitled “Bryoid Compositions, Methods of Making and Use Thereof,” is for the composition of matter of novel Bryostatins, methods of manufacturing, and use in the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson, Down’s syndrome, Hutchinson, Multiple Sclerosis and other spongiform encephalopathies; virus latency diseases such as HIV and Herpes; cancer; and amyloid mediated diseases such as glaucoma.
Bryoids consist of a family of Bryostatins, such as Bryostatin-1, that are complex cyclic macrolide molecules. Bryoids were originally isolated from the marine bryozoan, Bugula neritina, in small quantities. Methods of synthesis are complex and costly. Twenty-one Bryoid compositions, known as Bryostatins and numbered 1-21, have been identified. Many of the Bryoids are known to possess anticancer activities.
According to Dr. Trevor P. Castor, President and CEO, Aphios Corporation, and inventor of this patent: “These new Bryoids, Bryostatin-22 and Bryostatin-23, are highly potent nanomolar activators of a-secretase activity in neuroblastoma cell models, being more effective than Bryostatin-1 at increasing activity of all protein kinase C (PKC) isoforms, particularly the novel PKC isoforms, delta and epsilon. Aphios is developing these compounds for Alzheimer’s Disease, HIV-1 latency and Multiple Sclerosis, and is seeking collaborative research partners.”
About Aphios Corporation: Aphios Corporation (www.aphios.com) is a clinical stage, biotechnology company developing green enabling technology platforms for improving drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety. Based on these platforms, Aphios is developing enhanced therapeutics for health maintenance and disease prevention, and the treatment of cancer and supportive care, infectious diseases such as HIV, and neurological disorders such as Alzheimer’s disease, Multiple Sclerosis and Opioid use disorder.